Skip to content

The evaluation of clinical efficacy and safety of anal reconstruction in situ

The evaluation of clinical efficacy and safety of anal reconstruction in situ

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500097637
Enrollment
Unknown
Registered
2025-02-24
Start date
2025-02-24
Completion date
Unknown
Last updated
2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Locally advanced rectal cancer or acquired anal lesions

Interventions

Anal reconstruction in situ group:NA

Sponsors

Yangpu Hospital, Tongji University School of Medicine, Shanghai
Lead Sponsor

Eligibility

Sex/Gender
All
Age
6 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed with locally advanced rectal cancer or acquired anal lesions; 2. After discussion by a multidisciplinary team, it is considered that anal reconstruction in situ can be performed; 3. The patient is in good physical condition and can tolerate the surgery.

Exclusion criteria

Exclusion criteria: 1. The patient's general physical condition cannot tolerate surgery; 2. The patient has unresectable local or distant metastases

Design outcomes

Primary

MeasureTime frame
Postoperative anal function;Postoperative complications;

Secondary

MeasureTime frame
Disease-free survival;

Countries

China

Contacts

Public ContactHuihong Jiang

Yangpu Hospital, Tongji University School of Medicine, Shanghai

jiang572579@163.com+86 150 0008 5783

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026